Mavenir and HCL Collaborate on Integration and Delivery of O-RAN Compliant Radios
14.10.2021 16:00:00 EEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced a strategic partnership with HCL Technologies (HCL), a leading global technology company with expertise in network systems testing. This partnership helps accelerate the market availability of O-RAN split 7.2 compliant Remote Radiohead Units (RRUs) while establishing a business model to meet the growing demand and evolving requirements for O-RAN RRUs.
Today’s RRU ecosystem has expanded to offer Communication Service Providers (CSPs) a significantly wider choice of 2G, 3G, 4G, 5G, massive MIMO (mMIMO), millimeter Wave (mmWave), small cell and indoor radios. In turn, the number of RRU partners that Mavenir works with continues to grow, with each partner releasing new and sophisticated radios, with new software, across different radio technologies, output power, antenna dimensions and spectrum to meet the evolving needs of O-RAN customers.
The collaboration brings together HCL’s platform for third-party RRU testing and Mavenir’s full Centralized Unit (CU) and Distributed Unit (DU) RAN software stacks. RRU vendors will, as a result, be given the ability to work directly with HCL to assess their O-RAN interfaces and integrate with Mavenir’s O-RAN compliant cloud-native CU/DU software.
By simplifying testing and validation across multiple O-RAN interoperability profiles, the collaboration will help vendors fast-track validation of frequency variants and the increasingly diverse RRU offerings being demanded by the O-RAN market.
This partnership will benefit both RRU vendors and CSPs by supporting the continued expansion of the radio ecosystem and helping to establish a self-sustaining RRU business model:
- Vendors will be able to rapidly validate their O-RAN compliant RRUs as they develop portfolios of products targeted at different deployment scenarios.
- CSPs will be able to more easily identify the available O-RAN compliant RRU options for specific use cases and locations.
“We are directly addressing requests from customers and partners to speed the integration of new RRU products. The growing scale of the O-RAN industry now demands such a model. And thanks to O-RAN and open interfaces, new players such as HCL can enter the market to effectively serve the market needs,” said Mavenir’s Puneet Sethi, SVP/GM RAN Business Unit. “As more O-RAN RRU products become available and RRU partners are enabled to respond rapidly to their customers, CSPs worldwide will be able to take advantage of the full range of their spectrum assets and benefit from the rapidly accelerating RRU ecosystem.”
“The Mavenir-HCL partnership helps accelerate the O-RAN market, bringing a new suite of product offerings to CSPs and enterprises alike. This sets the stage for a nascent ecosystem accelerating future innovation across key verticals on a global scale,” said HCL’s Rajiv Shesh, Corporate Vice President, Engineering and R&D Services. “HCL is bringing together many decades of network testing experience, 5G expertise, state of the art lab facilities and advanced automation tools to validate the interoperability between Mavenir and RRU partners. HCL provides the necessary visibility and reporting capability that enables operators and enterprises in deploying best-of-breed Mavenir O-RAN solutions.”
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005064/en/
Contact information
Maryvonne Tubb
Mavenir
PR@mavenir.com
Casey Bush
GlobalResultsPR (US)
mavenir@globalresultspr.com
Kevin Taylor
GlobalResultsPR (EMEA)
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release
Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 14:00:00 EEST | Press release
Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom